A U.S. Food and Drug Administration advisory committee voted 3 to 6 against the benefit-risk profile of AstraZeneca's breast cancer drug camizestrant, according to AstraZeneca. This decision creates uncertainty for thousands of American patients battling HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation.
Despite camizestrant's significant efficacy in Phase III trials, this vote means AstraZeneca faces a prolonged and challenging path to US market approval. The company will likely prioritize European market entry, creating a disparity in patient access.
A Transatlantic Divide on Camizestrant's Approval
An EU panel has backed camizestrant's approval, according to FirstWord Pharma. In stark contrast, the FDA's Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote for camizestrant's benefit-risk profile in combination with a CDK 4/6 inhibitor for 1st-line treatment of HR-positive, HER2-negative advanced breast cancer with emergent ESR1 mutation, according to AstraZeneca. This transatlantic divide points to a complex regulatory path ahead for AstraZeneca.
Strong Clinical Data Meets Regulatory Skepticism
The SERENA-6 Phase III trial showed a 56% reduction in disease progression or death with the camizestrant combination versus standard-of-care, according to AstraZeneca. Median PFS was 16.0 months for camizestrant patients, compared to 9.2 months for the comparator arm. Yet, the FDA's ODAC rejection shows that compelling efficacy alone may not overcome US regulatory scrutiny if the benefit-risk profile for specific patient populations remains unclear.
Understanding the US Advisory Vote
The ODAC committee's 3 to 6 vote against camizestrant's benefit-risk profile, according to AstraZeneca, reveals significant concerns among independent advisors. These concerns will heavily influence the FDA's final decision, creating a significant hurdle for the drug's US market entry.
